Information Provided By:
Fly News Breaks for July 28, 2016
RGLS
Jul 28, 2016 | 07:10 EDT
Wells Fargo cut its price target on Regulus after the FDA requested detailed safety data about the company's HCV drug, RG-101, as well as information regarding the drug's potential impact on hepatoxicity and a risk/benefit assessment for the proposed therapeutic regimens containing RG-101. Wells thinks that there is some risk that the "FDA may not see the benefit of a 4-week or shorter course of HCV treatment." However, the firm says that the stock's risk/reward ratio remains positive, and it keeps an Outperform rating.
News For RGLS From the Last 2 Days
There are no results for your query RGLS